Changes in Hong Kong stocks | Biosetu-B (02315) rose more than 6%, industry sentiment continued to rise, animal models and pre-clinical efficacy businesses maintained high growth

The Zhitong Finance App learned that Biosetu-B (02315) rose more than 6%. As of press release, it had risen 6.24% to HK$59.6, with a turnover of HK$87.2941 million.

According to news, in the first half of this year, Baiosetu achieved revenue of 940 million yuan, an increase of 51.6% over the previous year; net profit to mother was 240 million yuan, a sharp increase of 402% over the previous year. During the reporting period, the total revenue of the preclinical sector was 723 million yuan, up 57.9% year on year, of which sales revenue of innovative animal models was 446 million yuan, up 62.4% year on year; pre-clinical pharmacological efficacy evaluation revenue was 243 million yuan, up 57.0% year on year. Meanwhile, at the beginning of this month, Baiosetu announced that it had reached a non-exclusive licensing cooperation with Qilu Pharmaceutical for all-human nanoantibody molecules to support the development of innovative drugs in the neurological field.

China Post Securities pointed out that the industry's boom continues to rise, compounded by the resonance of overseas expansion, and the animal model+pre-clinical efficacy business has maintained a high growth rate. Shen Wan Hongyuan believes that the company has formed a core business axis of dual-round development with model animal+mouse and mouse, and has an in-depth layout of domestic and foreign markets. With closed technology, data barriers, global layout, and AI, it is expected to grow into the world's leading innovation platform for antibody drugs.